# Clinical Prediction Model (CPM) Development Framework

[cite_start]This repository provides a structured, step-by-step implementation of the framework for developing and validating clinical prediction models, based on the 13-step guide published in **The BMJ**[cite: 12, 51].

## 📌 Overview
[cite_start]Published studies often have severe methodological limitations that undermine their usefulness[cite: 18]. [cite_start]This framework aims to help researchers avoid common pitfalls—such as overfitting, inappropriate categorization, and lack of sound performance assessment [cite: 39][cite_start]—by following a rigorous 13-step pipeline[cite: 37].

---

## 🚀 The 13-Step Methodology

### Phase 1: Inception & Design
* [cite_start]**Step 1: Define Aims & Create a Team**: Clearly determine the target population, outcome, healthcare setting, and intended users [cite: 37, 72-85]. [cite_start]Assemble a multidisciplinary team including clinicians, methodologists, and users[cite: 38, 91].
* [cite_start]**Step 2: Model Selection**: Choose between developing a new model or updating/recalibrating an existing one[cite: 104, 111].
* [cite_start]**Step 3: Define Outcome Measure**: Prioritize continuous and time-to-event measures; avoid arbitrary dichotomization to prevent loss of information [cite: 122-126].
* [cite_start]**Step 4: Candidate Predictors**: Identify potential predictors based on literature and expert knowledge, prioritizing those with suspected causal relationships[cite: 131, 144].

### Phase 2: Data Engineering & Power
* [cite_start]**Step 5: Data Collection & Examination**: Address potential measurement errors and exclude predictors with limited variation[cite: 169, 176].
* [cite_start]**Step 6: Sample Size Calculation**: Ensure the dataset is sufficient to support the number of model parameters to prevent overfitting [cite: 201-204].
* [cite_start]**Step 7: Missing Data Handling**: Use **Multiple Imputation** to handle uncertainty; avoid relying solely on complete cases [cite: 221-224].

### Phase 3: Development & Validation
* [cite_start]**Step 8: Fit the Model**: Use statistical models (e.g., Logistic, Cox) or machine learning [cite: 253-255]. [cite_start]Apply **penalization** (LASSO, Ridge, Elastic Net) to control complexity and bring the model to the "sweet spot" of the bias-variance trade-off [cite: 292-296].
* [cite_start]**Step 9: Assess Performance**: Evaluate both **Discrimination** (ranking ability) and **Calibration** (agreement between predicted and observed outcomes) [cite: 321-326].
* [cite_start]**Step 10: Final Model Selection**: Choose the final model based on validation metrics, preferring simpler models if performance is similar [cite: 453-455].

### Phase 4: Utility & Dissemination
* [cite_start]**Step 11: Decision Curve Analysis (DCA)**: Assess clinical utility by calculating the **net benefit** of using the model across clinically relevant thresholds[cite: 460, 467].
* [cite_start]**Step 12: Predictor Importance**: (Optional) Evaluate individual contributions through coefficients or performance reduction analysis [cite: 491-501].
* [cite_start]**Step 13: Reporting & Publication**: Follow the **TRIPOD statement** and ensure the model is accessible via full equations or web calculators (e.g., R-Shiny) [cite: 508-516].

---

## 📖 Key Concepts
* [cite_start]**Discrimination**: Capacity to distinguish between patients with different outcomes[cite: 322].
* [cite_start]**Calibration**: The agreement between predicted and observed outcomes[cite: 326].
* [cite_start]**Overfitting**: When a model performs well in the training set but fails in new data[cite: 69].
* [cite_start]**Optimism**: The difference between apparent and true model performance[cite: 69].

## 🛠 Required Guidelines & Tools
* [cite_start]**Reporting**: [TRIPOD Statement](https://www.tripod-statement.org/)[cite: 34].
* [cite_start]**Risk of Bias**: [PROBAST Tool](https://www.probast.org/)[cite: 35].
* [cite_start]**Sample Size**: `pmsampsize` package in R[cite: 774].

---

> **Note**: This repository is maintained for educational and research purposes, aiming to promote reproducible and high-quality prognostic research in medicine.
